EMA guideline: no way...: [Design Issues]

posted by mittyri – Russia, 2019-12-07 21:58 (1595 d 23:31 ago) – Posting: # 20959
Views: 5,987

Dear Osama,

❝ I also agree about this as a previous acadmic person, but as a regulator, which regulatory supportive Guidelines (EMA & FDA) reasons, can I rely on it to be able to use data from study subjects who didn't completed all study periods?


I doubt that something exists at the moment.
Please also see the related discussion and cites of EMA guideline.

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,655 registered users;
35 visitors (0 registered, 35 guests [including 8 identified bots]).
Forum time: 22:30 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5